AKT1 and metabolic dysfunction-associated steatotic liver disease: Collectively, these findings suggest that Nar may ameliorate MASLD by modulating the PI3K-AKT signaling cascade through direct interactions with key proteins, providing novel mechanistic insights and potential therapeutic implications.